The structure of Acepromazine
Find information on thousands of medical conditions and prescription drugs.

Acepromazine

Acepromazine or Acetylpromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a means of chemical restraint. Its principal value is in quietening and calming frightened and aggressive animals. The standard pharmaceutical preparation, acepromazine maleate, is used extensively in equine, feline, and canine; especially as a pre-anesthetic agent.

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Enteral Feeding Preserves Gut Th-2 Cytokines Despite Mucosal Cellular Adhesion Molecule-1 Blockade
From JPEN: Journal of Parenteral and Enteral Nutrition, 1/1/05 by Genton, Laurence

ABSTRACT. Background: Parenteral nutrition (PN) decreases gut-associated lymphoid tissue (GALT), the intestinal IgA stimulating cytokines IL-4 and IL-10 in gut homogenates, intestinal IgA levels and the expression of Peyer patch (PP) mucosal cellular adhesion molecule-1 (MAdCAM-1), an adhesion molecule found on the high endothelial venules of PP and other tissues. IL-4 in PP stimulates MAdCAM expression in vitro. MAdCAM-1 blockade with MECA-367 reduces GALT cell populations to PN levels but maintains intestinal IgA levels if the animals are chow fed. This study compares IL-4 levels in PP of chow and PN fed mice and measures the effects of MAdCAM blockade on IL-4 and IL-10 levels in gut homogenates of chow fed mice. We hypothesized that in vivo IL-4 levels drop in PP of PN fed mice and IL-4 and IL-10 levels are maintained after MAdCAM-1 blockade in chow fed mice. Methods: Exp 1: 18 mice received chow or PN for 5 days to determine PP IL-4 levels. Exp 2: 44 mice were randomized to chow + control monoclonal antibody (mAb), chow + MECA-367 (anti-MAdCAM-1 mAb) or PN for 4 days before measurement of IL-4 and IL-10 levels in gut homogenates. Results: Exp 1: IL-4 levels in vivo were lower in PP of PN-fed mice than chow fed mice (92.0 ± 15.1 pg/mL vs 251.1 ± 14.8, p = .0003). Exp 2: IL-4 levels were significantly higher in chow + control mAb (187.1 ± 44.1 pg/mL) and chow + MECA-367 (110.9 ± 19.1 pg/mL) groups than PN mice (21.8 ± 30.6 pg/mL, p

Lack of enteral stimulation during patenteral support of nutritional status increases the risk of infectious complications, especially pneumonia and intraabdominal abscesses in critically injured patients.1 Experimentally, at least part of this defect appears related to impaired mucosal immunity through reduction in cell numbers,2 reduction in Th-2 type IgA stimulating cytokines (IL-4 and IL-10) obtained from gut homogenates3 and isolated lamina propria cells,4 and depressed IgA levels produced by the mucosal-associated lymphoid tissue. Primary sites for sensitization of cells for intestinal and extra intestinal mucosal immunity are the Peyer patches (PP) of the small intestine. α4β7 And L-selectin on naïve T- and B-lymphocytes interact with the adhesion molecules, mucosal addressin adhesion molecule-1 (MAdCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on the vascular endothelium of the PP. This interaction initiates migration of naïve cells into the mucosal immune system.

MAdCAM-1 appears to be the most important of the PP-associated adhesion molecules because blockade of its site with an anti-MAdCAM-1 (MECA-367) monoclonal antibody (mAb) inhibits lymphocyte homing into the GALT and reduces cell numbers in the PP, lamina propria, and intraepithelial space, whereas ICAM-1 blockade does not. These histologic findings are similar to those found in mice fed parenteral nutrition (PN) with no enteral stimulation.2,5 Surprisingly, as long as enterai stimulation with chow feeding is not interrupted, MAdCAM-1 blockade does not destroy functional mucosal immunity as PN does (ie, MAdCAM-1 does not reduce intestinal IgA levels with complete loss of antibacterial defenses).5 The explanation for this paradox is not clear, but we previously speculated enterai stimulation preserved intestinal Th-2 cytokine levels, despite reduction in absolute cell numbers with MECA-367. In addition, IL-4 appears to stimulate in vitro MAdCAM-1 expression in some tissues, which might explain the reduced PP MAdCAM-1 expression during PN.5 Although we previously measured IL-4 and IL-10 cytokines and mRNA, these measurements were in gut homogenates or isolated lamina propria cells and not in isolated PP.3,4

The purpose of this study was to evaluate IL-4 and IL-10 levels in gut homogenates of chow-fed mice manipulated with MECA-367 and examine IL-4 levels in the PP of chow- and PN-fed mice. We hypothesized that enterai feeding preserves IL-4 and IL-10 levels despite MAdCAM blockade and that parenteral feeding reduces IL-4 levels in PP compared with chow feeding.

MATERIALS AND METHODS

Animals

The Animal Care and Use Committee of The University of Wisconsin-Madison approved all experimental protocols. Male ICR (Institute of Cancer Research) outbred mice were purchased from Harlan Co. (Madison, WI) and housed in an American Association for Accreditation of Laboratory Animal Care-accredited conventional facility. The environment was controlled with regard to temperature and humidity with a 12-hour light:dark cycle. Mice were fed ad libitum chow (LabDiet 5001; PMI International, Brentwood, MO) and water for 2 weeks before entry into protocols.

Surgical Procedure

After randomization to feeding groups, all mice were cannulated under ketamine hydrochloride (100 mg/kg body weight) and acepromazine maleate (10 mg/kg body weight) anesthesia. The proximal end of the silicone catheter (0.3 mm ID and 0.6 mm OD; Helix Medical, Carpinteria, CA) was inserted into the vena cava through the right jugular vein, whereas the distal end was run subcutaneously over the spine and exited at the midpoint of the tail. Catheterized mice were placed into metal metabolism cages with wire grid floors to eliminate coprophagia and were partially immobilized by their tail to insure catheter integrity for PN (PN) infusion. This does not seem to cause any physical or biochemical stress.6 After connection to infusion pumps (Instech Laboratories, Plymouth Meeting, PA), all mice received 4 mL/d of 0.9% saline IV with ad libitum chow and water for 2 days before entering the feeding protocols.

Feeding Protocols

Exp 1: effect of route of feeding on IL-4 levels in PP. Eighteen mice were randomized to chow (n = 8) or PN (n = 10). Mice given chow received 4 mL/d of 0.9% saline IV with ad libitum chow and water. Mice given PN received 4 mL of PN on the first experimental day, 6 mL on the second day, and 10 mL thereafter (1426 kJ/kg/d nonprotein energy intake, 16.1 g/kg/d protein). The PN solution contained 16% proteins, 84% dextrose (5110 kJ/L), electrolytes, and multivitamins, with a nonprotein energy-nitrogen ratio of 533 kJ/g of nitrogen.

After 5 days of experimental feedings, mice were anesthetized, weighed, and killed by cardiac puncture. All PP were excised and placed in 1 mL of lysis buffer (10 mmol/L Tris base; BioRad Laboratories, Hercules, CA; +150 mmol/L NaCl; Sigma, St. Louis, MO; adjusted to a pH of 8.0 with HCl; LabChem Inc, Pittsburgh, PA), and 1 μL of protease inhibitors (2 mmol/L phenylmethylsulfonyl fluoride and 2 μg/mL of leupeptin, pepstatin A and aprotinin; Sigma). Samples were homogenized for 30 seconds. After adding 10 μL, of Triton X-100 (Sigma), homogenates were centrifuged at 15,000 rpm for 45 minutes at 40C. IL-4 levels were measured in the supernatants using enzyme-linked immunosorbent assay (ELISA).

Exp 2: effects of MAdCAM-1 blockade on IL-4 and IL-10 levels in gut homogenates. Forty-four mice were randomized to chow + isotype control mAb (R35-95, rat IgG2^sub aκ^ isotypic Ab; PharMingen Inc, San Diego, CA; n = 14), chow + MECA-367 (rat IgG2^sub aκ^, PharMingen Inc; n = 15) or PN (n = 14). MECA-367 and the isotype control mAb were injected IV at a loading dose of 20 μg/d on the first experimental day and 10 μg/d thereafter. MECA-367 is a specific anti-MAdCAM-1 mAb. These doses were chosen because 10 μg of MECA-367 per saturates all cell binding sites in mice, resulting in significant drops in GALT cell mass to PN levels.5 The TPN solution and infusion protocol were the same as in experiment 1.

After 4 experimental days, mice were anesthetized, weighed, and killed by cardiac puncture. From the proximal, middle, and distal intestine, 0.5 g of intestines were harvested and homogenized as the PP described in experiment 1 but using 2 mL of lysis buffer, 2 μL of protease inhibitors, and 20 μL of Triton X-100.3 IL-4 and IL-10 levels in the supernatants were determined by ELISA. Four days were chosen because of our observation that maximal cellular changes had occurred after 3 days.

ELISA

IL-4 and IL-10 levels in intestinal homogenates were measured by using rat antimouse IL-4 or IL-10 antibodies to coat the plates, horseradish peroxidaseconjugated goat antimouse IL-4 and IL-10 as secondary antibodies, and recombinant mouse IL-4 and IL-10 as standards (Endogen, Woburn, MA). Intestinal and nasal IgA levels were measured by coating the plates with polyclonal goat antimouse IgA and using a horseradish peroxidase-conjugated goat antimouse IgA as a secondary antibody and mouse IgA^sub κ^ as the standard (Sigma Chemical Co).

Statistics

Statistical analysis was performed with Statview 5.0 (SAS Institute, Gary, NC, USA). Results are shown as mean ± SE. Groups were compared with analysis of variance followed, in case of significance, by Fisher's protected least significant difference post hoc test. Significance was set at p

RESULTS

Experiment 1

There was no significant difference in starting weights between the 2 groups. Weight loss did not differ between groups (chow: -1.3 ± 1.4 g; PN: -2.3 ± 1.9; p = .19). IL-4 levels were significantly higher in the PP after chow than after PN feeding (251.1 ± 14.8 pg/mL vs 92.0 ± 15.1 pg/mL, p = .0003).

Experiment 2

There was no difference in starting weights between the 3 groups. Weight loss was higher in PN-fed mice (- 5.0 g) than in mice fed chow + isotype control mAb (-1.7 g, p

DISCUSSION

Parenteral feeding with no enteral stimulation (ie, gut "starvation") prevents lethal malnutrition from starvation in mice, but it generates diffuse effects upon the common mucosal immune system within days. Lack of enteral feeding reduces IgA, a basic innate, but specific, immune response within the intestine and respiratory tract. Our prior work showed that this occurs through reductions in MAdCAM-1 expression in PP, decreases in T- and B-lymphocyte numbers in the PPs and lamina propria, and drops in the Th-2 type IgA stimulating cytokines IL-4 and IL-10 in the intestine and mRNA in isolated lamina propria cells. Blockade of MAdCAM-1 induces similar cellular effects. The current work shows that PP levels drop with PN. It also demonstrates that Th-2 cytokines are maintained after MAdCAM-1 blockade despite reductions in cell populations to levels of PN-fed mice as long as enteral feeding is maintained. The work also suggests that the role of Th-2 cytokines in mucosal immunity may differ, dependent upon the site of function and local needs.

One of the early changes seen with gut "starvation" is a rapid decrease in MAdCAM-1 expression on the high endothelial venules of the PP, with no effect on MAdCAM-1 in non-PP sites.7 MAdCAM-1 is the primary endothelial binding adhesion molecule attracting naïve α4β7+/L-selectin + lymphocytes into the mucosal immune system for sensitization in the PP and subsequent distribution to diffuse mucosal sites.8-10 MAdCAM-1 in PP is modified with a carbohydrate molecule, which is especially attractive to L-selectin, a ligand strongly expressed on naïve lymphocytes. This carbohydrate molecule distinguishes it from the form found in non-PP sites, which render the molecule more attractive to α4β7. Increased expression of α4β7 occurs on lymphocytes once they are sensitized in the PP. Blockade of α4β7 or L-selectin on circulating cells or MAdCAM-1 on the PP reproduces the decrease in Tand B-cell numbers to levels of PN-fed mice. Interestingly, MAdCAM-1 blockade does not severely impair antibacterial defenses nor IgA levels,5 even with reduced cell numbers within the lamina propria and PP, as long as animals have access to chow. This is most likely because of the high levels of IL-4 and IL-10 relative to the number of cells present in the lamina propria. Although the levels are somewhat less than animals given the control antibody, reflecting some effect of MAdCAM-1 blockade, they are adequate to maintain effective, though slightly less vigorous, mucosal defenses and are significantly higher than PN-fed mice.

These results suggests that the role of Th-2 cytokines may differ, depending on the intestinal site of action or the form of MAdCAM-1. In the PP where MAdCAM-1 is found in the modified form, IL-4 levels were significantly depressed in PN-fed mice, supporting our hypothesis that IL-4 depression in PP might impair MAdCAM-1 expression, consistent with observed effects of IL-4 on MAdCAM-1 in some tissues.11 In addition, Kerlin and Pike12 noted an increase in the number of immunoglobulin-secreting cells in the murine PP with administration of rIL-4. We hoped this could be definitely determined by administering rIL-4 exogenously to maintain physiologic tissue levels. We embarked on experiments administering large amounts of IL-4/Fc fusion proteins designed to maintain high circulating levels of IL-4, but clearance rates were unexpectedly rapid, which failed to maintain high serum IL-4 levels. We could not document any beneficial effects upon GALT cell mass or IgA levels with the fusion protein.

Different mechanisms may be occurring in non-PP sites such as the lamina propria where cytokines may function to control IgA rather than MAdCAM-1. MAdCAM-1 in this site is unmodified and is not affected by PN or the associated decrease in Th-2 cytokines.7 In fact, several studies found an inverse relationship between MAdCAM-1 expression and Th-2 cytokine levels, especially IL-10 in non-PP sites. McDonald et al13 described decreased IL-10 transcripts in the colon and cecum of colitic IL-2 knockout mice in association with an increased number of MAdCAM-1 positive endothelial cells. Colitic IL-10 knockout mice showed higher transcripts and expression of MAdCAM-1 in the colon than wild-type mice.14,15 IL-10 inhibits MAdCAM-1 expression16 in vivo and transfection of IL-10 expression vectors into high endothelial venules reduce MAdCAM-1 dependent lymphocyte adhesion.17 Although these studies in inflamed colonic tissue suggest an inhibitory role of the Th2 cytokine IL-10 on MAdCAM-1 expression in the colon, we were unable to detect intestinal changes in intestinal MAdCAM-1 expression despite dramatic alterations in gut and lamina propria Th-2 cytokines or their mRNA.3,4,7

The reasons for the decrease in PP IL-4 with PN and the preservation of the cytokines with MAdCAM-1 blockade are unclear, but oral tolerance may play a role. Under physiologic conditions, enteral feeding elicits oral tolerance, a state of systemic immune hyporesponsiveness to low doses of dietary antigens. Gonella et al18 described up-regulation of IL-4, IL-10, and TGF-β in the murine GALT after low doses of ovalbumin or oligodendrocyte glycoprotein. Oral tolerance to proteins such β-lactoglobulin or ovalbumin have been associated with increased PP IL-4 production and secretion.19,20 Thus, absence of intestinal food antigens may explain the reduced PP IL-4 and lamina propria IL-4 and IL-10 levels in PN-fed mice. Chow feeding and associated oral tolerance stimulation may be sufficient to preserve levels of Th-2 cytokines and IgA levels despite MAdCAM-1 blockade.

In summary, IL-4, a stimulant of MAdCAM-1 expression, is decreased in the PP of animals parenterally fed or known to have decreased expression of MAdCAM-1 on the high endothelial venules. With enterai feeding, MAdCAM-1 blockade using MECA-367 preserved IL-4 and IL-10 levels at normal or supernormal levels with normal IgA levels, despite cellular depletion. Physiologically, enteral feeding maintains mucosal defenses despite impairment of molecules important for cellular distribution in mucosal-associated lymphoid tissues.

REFERENCES

1. Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992;215:503-513.

2. Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-Henken B. Effects of parenteral and enteral nutrition on gutassociated lymphoid tissue. J Trauma. 1995;39:44-52.

3. Wu Y, Kudsk KA, DeWitt RC, Tolley EA, Li J. Route and type of nutrition influence IgA-mediating intestinal cytokines. Ann Surg. 1999;229:662-668.

4. Fukatsu K, Kudsk KA, Zarzaur BL, Wu Y, Hanna MK, DeWitt RC. TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Shock. 2001; 15:318-322.

5. Ikeda S, Kudsk KA, Fukatsu K, et al. Enteral feeding preserves mucosal immunity despite in vivo MAdCAM-1 blockage of lymphocyte homing. Ann Surg. 2003;237:677-685.

6. Sitren HS, Heller PA, Bailey LB, Gerda JJ. Total parenteral nutrition in the mouse: development of a technique. JPEN J Parenter Enteral Nutr. 1983;7:582-589.

7. Zarzaur BL, Fukatsu K, Johnson CJ, Eng E, Kudsk KA. A temporal study of diet-induced changes in Peyer patch MAdCAM-1 expression. Surg Forum. 2001;52:194-196.

8. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Rutcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331:41-46.

9. Sikorski EE, Hallmann R, Berg EL, Butcher EC. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-α and IL-I. J Immunol. 1993;151:5239-5250.

10. Rott LS, Briskin MJ, Andrew DP, Berg EL, Butcher EC. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1: comparison with vascular cell adhesion molecule-1 and correlation with β7 integrins and memory differentiation. J Immunol. 1996;156: 3727-3736.

11. Mueller R, Krahl T, Sarvetnick N. Tissue-specific expression of interleukin-4 induces extracellular matrix accumulation and extravasation of B cells. Lab Invent. 1997;76:117-128.

12. Kerlin RL, Pike BL. Spontaneous and cytokine-inducible "natural" immunoglobulin secreting cells in organized lymphoid tissues of mice. Immunol Cell Biol. 1991;69:167-175.

13. McDonald SA, Palmen MJ, Van Rees EP, MacDonald TT. Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology. 1997;91:73-80.

14. Kawachi S, Jennings S, Panes J, et al. Cytokine and endothelial cell adhesion molecule expression in intcrleukin-10-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2000;278:G734-G743.

15. Connor EM, Eppihimer MJ, Morise Z, Granger DN, Grisham MB. Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. J Leukoc Biol. 1999;65:349-355.

16. Oshima T, Pavlick K, Grisham MB, et al. Glucocorticoids and IL-10, but not 6MP, 5ASA of sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease. Aliment Pharinacol Ther. 2001;15:1211-1218.

17. Sasaki M, Jordan P, Houghton J, et al. Transfection of IL-10 expression vectors into endothelial cultures attenuates α4β7dependent lymphocyte adhesion mediated by MAdCAM-1 [article online]. BMC Gastroenterol. 2003;3:3.

18. Gonnella PA, Waldner HP, Weiner HL. B cell-deficient (mu MT) mice have alterations in the cytokine microenvironment of the gut-associated lymphoid tissue (GALT) and a defect in the low dose mechanism of oral tolerance. J Immunol. 2001;166:44564464.

19. Kato C, Sato K, Eishi Y, Nakamura K. The influence of initial exposure timing to β-lactoglobulin on oral tolerance induction. J Allergy Clin Immunol. 1999;104:870-878.

20. Marth T, Ring S, Schulte D, et al. Antigen-induced mucosal T cell activation is followed by Th1 T cell suppression in continuously fed ovalbumin TCR-transgenic mice. Bur J Immunol. 2000;30:3478-3486.

Laurence Genton, MD[dagger]; Kenneth A. Kudsk, MD*[dagger]; Shannon R. Reese, BS[dagger]; and Shigeo Ikeda, MD, PhD[dagger]

From the *Veterans Administration Surgical Services, William S. Middleton Memorial Veterans Hospital Madison, Wisconsin; and the [dagger]University of Wisconsin Medical School, Department of Surgery, Madison, Wisconsin

Received for publication August 16, 2004.

Accepted for publication October 11, 2004.

Grant support: NIH grant ROl GM53439-06A1.

Correspondence: Kenneth A. Kudsk, MD, University of Wisconsin Medical School, Department of Surgery, H4/730 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-7375. Electronic mail may be sent to kudsk@surgery.wisc.edu.

Copyright American Society for Parenteral and Enteral Nutrition Jan/Feb 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Acepromazine
Home Contact Resources Exchange Links ebay